Natera Q4 prelim revenue beats on oncology tests boost

Natera

12/01/2026 05:35

Overview

Cell-free DNA leader's preliminary Q4 revenue rose 39%, beating analyst expectations

Company processed 55% more oncology tests in Q4 2025 compared to Q4 2024

Outlook

Natera expects 2025 revenues to increase by 35% compared to 2024

Company projects 2025 revenue to exceed previous forecast by $40 mln

Natera plans to present additional business updates at J.P. Morgan Conference

Result Drivers

ONCOLOGY TESTING - Significant growth in oncology tests, particularly MRD tests, drove Q4 results with a 55% increase in processed tests compared to Q4 2024

RECORD TEST VOLUME - Company processed a record number of clinical MRD tests in Q4 2025, despite fewer days to receive samples

REVENUE GROWTH - Total revenue increased by 39% in Q4 2025 compared to Q4 2024, driven by higher test volumes

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$660 mln
$571.46 mln (19 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Natera Inc is $257.50, about 9.9% above its January 9 closing price of $234.31

Press Release: ID:nBw9L7Qr3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)